Peripheral Neurotoxicity of Weekly Paclitaxel Chemotherapy: A Schedule or a Dose Issue?
Clinical Breast Cancer, ISSN: 1526-8209, Vol: 7, Issue: 7, Page: 550-554
2007
- 35Citations
- 39Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations35
- Citation Indexes35
- 35
- CrossRef16
- Captures39
- Readers39
- 39
Article Description
The rationale for intensification strategies is that more frequent exposure to chemotherapeutics could enhance antitumor activity. Several trials investigated weekly paclitaxel administration, but there are no clear data concerning peripheral neurotoxicity. The aim of this study was to assess the incidence of peripheral neurotoxicity in patients affected by advanced breast cancer treated with weekly paclitaxel. Neurotoxicity was assessed with neurologic and neurophysiologic evaluation before treatment and after 12 weeks and 24 weeks. A total neurotoxicity score was assigned to each patient on the basis of neurophysiologic and neuropathic signs and symptom changes. Seventeen patients entered the study. After 12 weeks of treatment, 71% showed moderate clinical and/or neurophysiologic signs of neurotoxicity; after 24 weeks, the incidence of neurotoxicity increased to 96%. Sural amplitude at the 24-weeks examination significantly decreased from basal mean value (13.5 μv, standard deviation [SD] 6 μv vs. 7 μv, SD 5.9 μv, respectively; P = 0.01), whereas median sensory amplitude decreased after 24 weeks from 10.3 μv, SD 6.2 μv to 4.9 μv, SD 3.8 μv ( P = 0.001). In a subset of 11 patients, we obtained a follow-up examination after 6 months from the end of treatment. In all patients, examined signs and symptoms of neurotoxicity improved with recovery of subjective neuropathic symptoms and neurophysiologic findings. Our results demonstrate, in a little population of patients evaluated with a comprehensive neurologic assessment, that weekly paclitaxel is related to a very high incidence of peripheral neurotoxicity. Follow-up data obtained in a subset of patients indicate that peripheral neurotoxicity is reversible.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1526820911707480; http://dx.doi.org/10.3816/cbc.2007.n.010; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=34248232644&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/17509163; https://linkinghub.elsevier.com/retrieve/pii/S1526820911707480; http://linkinghub.elsevier.com/retrieve/pii/S1526820911707480; http://cigjournals.metapress.com/index/10.3816/CBC.2007.n.010; http://api.elsevier.com/content/article/PII:S1526820911707480?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1526820911707480?httpAccept=text/plain; https://dx.doi.org/10.3816/cbc.2007.n.010
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know